MPMichael Patterson

Michael Patterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Patterson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BurstDR spinal cord stimulation for chronic regional pain syndrome secondary to Castleman’s disease treatment: A case report

    by Stephen Jaffee, Chinelo Onyiah, Michael D. Patterson, Griffin White, Mokshal H. Porwal, Nestor Tomycz

    Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.

  • Open Access

    BurstDR spinal cord stimulation for chronic inflammatory demyelinating polyneuropathy

    by Dmytro Iovenko, Stephen Jaffee, Michael Patterson, Nestor Tomycz

    Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder in which the immune system attacks the myelin sheath, leading to progressive muscle weakness and sensory loss. Neuropathic pain is a common and often debilitating symptom in patients with CIDP. Treatment options include immunoglobulin therapy and, in refractory cases, spinal cord stimulation (SCS). Case Description: We present the case of a 70-year-old male with CIDP who experienced severe neuropathic pain in a stocking distribution affecting both lower extremities. He had previously been treated with intravenous immunoglobulin with limited relief of his pain symptoms. Due to persistent, debilitating neuropathic pain despite ongoing immunotherapy, he underwent implantation of a thoracic paddle spinal cord stimulator. At 3-month postoperative follow-up, he reported a 75% reduction in pain intensity. Conclusion: BurstDR paddle lead SCS may offer significant pain relief in patients with CIDP-associated neuropathic pain and should be considered as part of a multidisciplinary treatment.


  • Open Access

    Successful relief of central poststroke pain with BurstDR spinal cord stimulation: A case series

    by Nisha L. Busch, Nathan Esplin, Michael Patterson, Nestor D. Tomycz

    Background: Central poststroke pain (CPSP) is a commonly undertreated condition that can negatively impact a patient’s quality of life. The efficacy of spinal cord stimulation (SCS) for the treatment of CPSP is not established due to limited studies. Case Description: Here, two patients, ages 42 and 75, sustained strokes resulting in CPSP. After failed medical management, both underwent placement of paddle-lead SCS systems utilizing BurstDR stimulation that successfully resulted in pain resolution. Conclusion: Two patients with CPSP were successfully treated with paddle lead SCS with BurstDR programming.